Date:8/27/2009

1,110 654,400 Prepaid, other current assets and other assets 625,462 743,951 Accounts payable and other accrued liabilities (8,332) (986,592) Other long-term obligations 47,856 582,254 ------ ------- Net cash provided by operating activities 2,901,883 1,268,592 --------- --------- Cash flows from investing activities: Additions to property and equipment (54,259) (85,863) Additions to patents (41,791) (34,551) ------- ------- Net cash used in investment activities (96,050) (120,414) ------- -------- Cash flows from financing activities: Costs of initial public offering (322,664) (154,179) Principal payments on note payable (916,668) (416,667) Net borrowings on line of credit 500,000 - Payment of other long-term obligations (2,760,000) - Costs of financing for long-term debt and credit facility - (15,475) Proceeds from exercise of stock options 39,098 4,296 Excess tax benefit derived from exercise of stock options 156,758 2,842,825 Payments made in connection with repurchase of common shares - (2,707,419) --- ----------- Net cash used in financing activities
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine news :

1. Orion ICG, LLC Announces Acquisition of Cumberland Therapy Services, Inc.
2. Cumberland Pharmaceuticals Announces Appointments
3. Cumberland Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 27, 2009
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes